Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie Healer

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Biorxiv : the Preprint Server for Biology|July 17, 2025
Navigating parasite antigen genetic diversity in the design of <i>Plasmodium vivax</i> serological exposure markers for malariaPaolo Bareng, Kenneth W Wu, Eizo Takashima, et al.
Nature|December 14, 2018
Structure of Plasmodium falciparum Rh5-CyRPA-Ripr invasion complexWilson Wong, Rick Huang, Sebastien Menant, et al.
The Lancet. Microbe|May 19, 2026
Assessing the effect of parasite antigen genetic diversity on performance of Plasmodium vivax serological exposure markers for malaria: a multicentre observational diagnostic accuracy studyAlison Paolo N Bareng, Kenneth W Wu, Eizo Takashima, et al.
Cell Reports. Medicine|June 22, 2022
Plasmodium vivax malaria serological exposure markers: Assessing the degree and implications of cross-reactivity with P. knowlesiRhea J Longley, Matthew J Grigg, Kael Schoffer, et al.
Elife|September 27, 2017
Identification of highly-protective combinations of <i>Plasmodium vivax</i> recombinant proteins for vaccine developmentCamila Tenorio França, Michael T White, Wen-Qiang He, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 19, 2013
Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker developmentJack S Richards, Thangavelu U Arumugam, Linda Reiling, et al.
Frontiers in Cellular and Infection Microbiology|January 6, 2023
RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical settingJulie Healer, Jennifer K Thompson, Karen L Mackwell, et al.
JCI Insight|June 15, 2021
High-dimensional mass cytometry identifies T cell and B cell signatures predicting reduced risk of Plasmodium vivax malariaLisa J Ioannidis, Halina M Pietrzak, Ann Ly, et al.
Vaccine|September 14, 2013
First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteersMichele Spring, Jittawadee Murphy, Robin Nielsen, et al.
Molecular Systems Biology|April 27, 2022
Molecular profiling reveals features of clinical immunity and immunosuppression in asymptomatic P. falciparum malariaStephanie I Studniberg, Lisa J Ioannidis, Retno A S Utami, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Biorxiv : the Preprint Server for Biology|July 17, 2025
Navigating parasite antigen genetic diversity in the design of <i>Plasmodium vivax</i> serological exposure markers for malariaPaolo Bareng, Kenneth W Wu, Eizo Takashima, et al.
Nature|December 14, 2018
Structure of Plasmodium falciparum Rh5-CyRPA-Ripr invasion complexWilson Wong, Rick Huang, Sebastien Menant, et al.
The Lancet. Microbe|May 19, 2026
Assessing the effect of parasite antigen genetic diversity on performance of Plasmodium vivax serological exposure markers for malaria: a multicentre observational diagnostic accuracy studyAlison Paolo N Bareng, Kenneth W Wu, Eizo Takashima, et al.
Cell Reports. Medicine|June 22, 2022
Plasmodium vivax malaria serological exposure markers: Assessing the degree and implications of cross-reactivity with P. knowlesiRhea J Longley, Matthew J Grigg, Kael Schoffer, et al.
Elife|September 27, 2017
Identification of highly-protective combinations of <i>Plasmodium vivax</i> recombinant proteins for vaccine developmentCamila Tenorio França, Michael T White, Wen-Qiang He, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 19, 2013
Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker developmentJack S Richards, Thangavelu U Arumugam, Linda Reiling, et al.
Frontiers in Cellular and Infection Microbiology|January 6, 2023
RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical settingJulie Healer, Jennifer K Thompson, Karen L Mackwell, et al.
JCI Insight|June 15, 2021
High-dimensional mass cytometry identifies T cell and B cell signatures predicting reduced risk of Plasmodium vivax malariaLisa J Ioannidis, Halina M Pietrzak, Ann Ly, et al.
Vaccine|September 14, 2013
First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteersMichele Spring, Jittawadee Murphy, Robin Nielsen, et al.
Molecular Systems Biology|April 27, 2022
Molecular profiling reveals features of clinical immunity and immunosuppression in asymptomatic P. falciparum malariaStephanie I Studniberg, Lisa J Ioannidis, Retno A S Utami, et al.
Pageof 6